Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years
Open Access
- 30 September 2020
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (10) , 940
Abstract
Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (16-30366A)
- Univerzita Karlova v Praze (PROGRES Q40/06)
This publication has 55 references indexed in Scilit:
- Doxorubicin-mediated radiosensitivity in multicellular spheroids from a lung cancer cell line is enhanced by composite micelle encapsulationInternational Journal of Nanomedicine, 2012
- Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)BMC Cancer, 2011
- Anti-PEG IgM Response against PEGylated Liposomes in Mice and RatsPharmaceutics, 2010
- Radiation Recall with Anticancer AgentsThe Oncologist, 2010
- Controlled application and removal of liposomal therapeutics: Effective elimination of pegylated liposomal doxorubicin by double‐filtration plasmapheresisin vitroJournal of Clinical Apheresis, 2010
- Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapyMedical Hypotheses, 2009
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patientsEuropean Journal of Cancer, 2003
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003